[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Shuangshoti S, Rushing EJ, Mena H, Olsen C, Sandberg GD: Supratentorial extraventricular ependymal neoplasms: a clinicopathologic study of 32 patients. Cancer; 2005 Jun 15;103(12):2598-605
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supratentorial extraventricular ependymal neoplasms: a clinicopathologic study of 32 patients.
  • BACKGROUND: Published research on the clinicopathologic features of extraventricular ependymal neoplasms of the cerebral hemispheres has been scant.
  • METHODS: Thirty-two archival cases were studied to investigate the prognostic impact of clinicopathologic parameters including flow cytometry, the proliferation (Ki-67) labeling index, and p53 expression.
  • The left cerebral hemisphere was 1.5 times more commonly involved.
  • Tumors expressed glial fibrillary acidic protein (87%), S-100 protein (77%), cytokeratin (43%), and epithelial membrane antigen (17%).
  • Ki-67 proliferation index paralleled tumor grade.
  • Flow cytometry performed in 27 tumors revealed diploidy in 20 cases and aneuploidy in 4 cases (3 anaplastic and 1 classic ependymomas), with S-phase fraction ranging from 0.2-9.7.
  • Eleven subjects were additionally treated with radiotherapy, and 3 with chemotherapy.
  • CONCLUSIONS: The results of the current study suggest that there is no significant relation between histopathology, Ki-67 proliferation index, p53 immunolabeling, tumor ploidy, and biologic behavior.
  • [MeSH-major] Brain Neoplasms / pathology. Cerebral Ventricle Neoplasms / pathology. Ependymoma / pathology. Glioma, Subependymal / pathology. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Proliferation. Child. Child, Preschool. Female. Flow Cytometry. Humans. Infant. Ki-67 Antigen / metabolism. Male. Middle Aged. Ploidies. Prognosis. S Phase. Tumor Suppressor Protein p53

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2005 by the American Cancer Society.
  • (PMID = 15861411.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


2. Brandes AA, Cavallo G, Reni M, Tosoni A, Nicolardi L, Scopece L, Franceschi E, Sotti G, Talacchi A, Turazzi S, Ermani M: A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. Cancer; 2005 Jul 1;104(1):143-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia.
  • BACKGROUND: No data on the role of chemotherapy in recurrent ependymal tumors are available in adults.
  • The aim of the current study was to investigate outcomes after salvage chemotherapy in this setting.
  • METHODS: A retrospective review was made of the charts of 28 adults (> or = 18 years) with progressive or recurrent ependymal tumors after surgery and radiotherapy, who received chemotherapy between 1993 and 2003 in 3 institutions of the Gruppo Italiano Cooperativo di Neuro-Oncologia network.
  • RESULTS: Thirteen patients (46.3%) received cisplatin-based chemotherapy (Group A) and 15 (53.7%) received regimens without cisplatin (Group B).
  • Platinum-based chemotherapy yielded 2 complete responses (CR) (15.4%) and 2 (15.4%) partial responses (PR), whereas 7 patients (53.8%) remained stable (SD).
  • After regimens without cisplatin, there were no CR, 2 PR (13.3%), and 11 SD (73.3%).
  • The overall median time to progression was 9.9 months (95% confidence interval [95% CI], 7.5-21.7 months), 9.9 months (5.2-not reached) for Group A and 10.9 months (95% CI, 7.17-23.9 months) for Group B.
  • The overall median survival (OS) was 40.7 months (95% CI, 16-not reached), 31 months (21-not reached) for Group A and 40.7 months (13.4-not reached) for Group B.
  • CONCLUSIONS: Cisplatin-based chemotherapy achieved a higher response rate, but did not prolong disease progression-free survival or OS.
  • More active regimens for the salvage treatment of ependymal tumors have yet to be found.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Ependymoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Italy. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Salvage Therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15912507.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


3. Maruyama K, Morita A, Shibahara J, Nakazato Y, Kirino T: Multifocal pilocytic astrocytomas with ependymal differentiation in the bilateral medial temporal lobes: case report. Neurol Med Chir (Tokyo); 2005 Aug;45(8):411-4
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal pilocytic astrocytomas with ependymal differentiation in the bilateral medial temporal lobes: case report.
  • Neuroimaging showed bilateral temporal lobe masses with calcification and cysts.
  • The histological diagnosis was pilocytic astrocytoma with ependymal differentiation and a MIB-1 staining index of up to 8.0%.
  • Adjuvant chemotherapy consisting of carboplatin and vincristine was given followed by radiotherapy.
  • Neuroimaging showed that the bilateral tumors had disappeared and showed no recurrence for 29 months after the diagnosis.
  • Pilocytic astrocytoma usually presents as a solitary mass in the cerebellum or optic pathway with low proliferative activity, but should be included in the differential diagnosis of multifocal tumors arising in the bilateral temporal lobes.
  • Ependymal differentiation with extremely high proliferative activity might be related to this unusual clinical presentation.
  • Intensive treatment is recommended for patients with such specific neuroimaging and histological features.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Temporal Lobe / pathology
  • [MeSH-minor] Antibodies, Antinuclear. Antibodies, Monoclonal. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Proliferation. Child. Diagnosis, Differential. Ependyma / pathology. Hemianopsia / etiology. Hemianopsia / pathology. Hemianopsia / physiopathology. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neurosurgical Procedures. Paresis / etiology. Paresis / pathology. Paresis / physiopathology. Radiotherapy. Seizures / etiology. Seizures / pathology. Seizures / physiopathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127260.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / MIB-1 antibody
  •  go-up   go-down


Advertisement
4. Agaoglu FY, Ayan I, Dizdar Y, Kebudi R, Gorgun O, Darendeliler E: Ependymal tumors in childhood. Pediatr Blood Cancer; 2005 Sep;45(3):298-303
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymal tumors in childhood.
  • BACKGROUND: Ependymal tumors are classified as ependymoma (benign or low grade) versus anaplastic ependymoma (malignant or high grade).
  • Ependymomas represent 5-10% of intracranial neoplasm in children.
  • In this study, demographic data and the treatment results of pediatric patients with ependymal tumors, treated in a single institute, is reported.
  • PATIENTS AND METHODS: Between 1989 and 2001, 40 (22 M/18 F) previously untreated patients with a median age of 5.5 years (3 months-15 years), of histologically proven ependymal tumors (except ependymoblastomas) were referred to the Institute of Oncology, University of Istanbul.
  • Total tumor resection was performed in 20 patients (50%), subtotal in 18 patients (45%), and biopsy only in 2 patients (5%).
  • Postoperative treatment consisted of regional (8 patients) or craniospinal (CSI) (9 patients) radiotherapy (RT) in patients with ependymoma; regional (7 patients) or CSI RT (14 patients) with chemotherapy (ChT) in patients with anaplastic ependymoma; ChT only (1 patient) in patients less than 3 years of age.
  • The standard technique for posterior fossa irradiation was parallel-opposed lateral fields and total dose was 45-54 Gy.
  • Median time for progression or relapse was 24.3 months and there were 19 patients (43.6%) with relapse or progression.
  • Non-metastatic patients (P = 0.0008, 5-year OS rate was 82% vs. 29%), and totally resected patients (P = 0.01, 5-year OS rate was 80% vs. 55%), and > or =3 years of age (P = 0.04, 5-year OS rate was 75% vs. 38%) had significantly better outcome.
  • CONCLUSIONS: The majority of complete responders were patients who had total tumor removal.
  • Treatment failure occurred mainly within the first 2 years, and outcome was dismal for patients who relapsed or had progressive disease.
  • [MeSH-major] Brain Neoplasms. Ependymoma
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Multivariate Analysis. Risk Factors. Survival Rate. Turkey / epidemiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15770637.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Brisson C, Lelong-Rebel I, Mottolèse C, Jouvet A, Fèvre-Montange M, Saint Pierre G, Rebel G, Belin MF: Establishment of human tumoral ependymal cell lines and coculture with tubular-like human endothelial cells. Int J Oncol; 2002 Oct;21(4):775-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of human tumoral ependymal cell lines and coculture with tubular-like human endothelial cells.
  • Ependymomas, rare neoplasms of the central nervous system, occur predominantly in children.
  • Treatment of ependymomas relies on surgery combined with radio- or chemotherapy, but the efficiency of chemotherapy is limited, probably because of their multidrug resistance (MDR) phenotype.
  • Progress in the therapy of these neoplasms is dramatically limited by the absence of cell line models.
  • Histological, immunological, and ultrastructural studies showed that the morphological features (microvilli, cilia, and caveolae) of these cultured cells were similar to those of the tumor in vivo.
  • The cells expressed potential oncological markers related to the immature state of tumoral cells (nestin and Notch-1), their tumorigenicity [caveolae and epidermal growth factor-receptor (EGF-R)], or the MDR phenotype [P-glycoprotein (P-gp)].
  • The expression of P-gp, EGF-R, and caveolin-1 by these tumoral ependymocytes could be useful in studies on new drugs.
  • This coculture model might represent a new powerful tool to study new therapeutic delivery strategies in tumoral cells.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Culture Techniques / methods. Endothelium, Vascular / cytology. Ependymoma / pathology. Tumor Cells, Cultured
  • [MeSH-minor] Adolescent. Adult. Aged. Cells, Cultured. Child. Child, Preschool. Coculture Techniques. Collagen / pharmacology. Drug Combinations. Female. Humans. Immunohistochemistry. Infant. Laminin / pharmacology. Male. Microscopy, Electron. Microscopy, Fluorescence. Middle Aged. P-Glycoprotein / metabolism. Proteoglycans / pharmacology. Time Factors. Umbilical Veins / cytology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12239616.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Laminin; 0 / P-Glycoprotein; 0 / Proteoglycans; 119978-18-6 / matrigel; 9007-34-5 / Collagen
  •  go-up   go-down


6. Moynihan TJ: Ependymal tumors. Curr Treat Options Oncol; 2003 Dec;4(6):517-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymal tumors.
  • Ependymal tumors are rare malignancies that arise from the cells that line the ventricles and central canal of the spinal cord.
  • Although they are more common in children, adults may also be effected by ependymal tumors.
  • Prognosis is dependent on tumor location, histology, especially for myxopapillary tumors that tend to occur in the lumbar spine, extent of surgical resection, and stage of disease.
  • Standard therapy consists of complete resection when feasible.
  • Patients with known residual disease may benefit from local radiation therapy, but the extent of radiation field and total dose are controversial.
  • Even in patients treated with involved field radiotherapy, most relapses occur within the original tumor bed, thus local control remains the biggest obstacle to effective therapy.
  • Chemotherapy has little impact against this tumor and has no role in the adjuvant setting, outside of a well designed clinical trial, with the possible exception of children younger than 5 years in an effort to delay radiation.
  • A minority of patients may respond to one of several chemotherapy regimens at the time of recurrence, but the impact of this therapy is limited.
  • Newer treatment strategies are needed.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Ependymoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Emergency Medical Services. Humans. Life Style. Neoplasm Staging. Neurosurgical Procedures. Radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1977 Aug;40(2):907-15 [890671.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1288-96 [11230470.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 2;95(7):532-9 [12671021.001]
  • [Cites] Med Pediatr Oncol. 1996 Jul;27(1):8-14 [8614396.001]
  • [Cites] Childs Nerv Syst. 1999 Oct;15(10):563-70 [10550587.001]
  • [Cites] Pediatr Neurol. 2001 Feb;24(2):117-21 [11275460.001]
  • [Cites] Pediatr Neurosurg. 1990-1991;16(2):57-65 [2132926.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):255-68 [12510777.001]
  • [Cites] Pediatr Hematol Oncol. 2002 Jul-Aug;19(5):295-308 [12078861.001]
  • [Cites] J Neurooncol. 1999;45(1):61-7 [10728911.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):287-95 [10661334.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3156-62 [15284268.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):953-8 [9869215.001]
  • [Cites] Med Pediatr Oncol. 1997 Aug;29(2):79-85 [9180907.001]
  • [Cites] Childs Nerv Syst. 1999 Jan;15(1):17-28 [10066016.001]
  • [Cites] J Neurosurg. 1998 Apr;88(4):695-703 [9525716.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):757-61 [11172959.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 15;28(2):381-6 [8276653.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] Neurosurgery. 1991 May;28(5):666-71; discussion 671-2 [1876244.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):997-1002 [12209682.001]
  • [Cites] Pediatr Neurosurg. 1996 Jul;25(1):7-12 [9055328.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):135-43 [9524092.001]
  • [Cites] Pediatr Neurosurg. 1998 Jul;29(1):40-5 [9755311.001]
  • [Cites] Cancer. 1997 Jul 15;80(2):341-7 [9217048.001]
  • (PMID = 14585232.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 28
  •  go-up   go-down


7. Mendrzyk F, Korshunov A, Benner A, Toedt G, Pfister S, Radlwimmer B, Lichter P: Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res; 2006 Apr 1;12(7 Pt 1):2070-9
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma.
  • Our aim was to screen for novel genomic imbalances and prognostic markers in ependymal tumors.
  • EXPERIMENTAL DESIGN: We analyzed 68 sporadic tumors by matrix-based comparative genomic hybridization using DNA microarrays containing >6,400 genomic DNA fragments.
  • Novel recurrent genomic gains were validated by fluorescence in situ hybridization using a tissue microarray consisting of 170 intracranial ependymomas.
  • Candidate genes were also tested for mRNA expression by quantitative real-time PCR, and protein expression was determined by immunohistochemistry on the tissue microarray.
  • RESULTS: Chromosomal gain of 1q correlated with pediatric patients (P = 0.004), intracranial ependymomas (P = 0.05), and tumors of grade III (P = 0.002).
  • Gain of 1q21.1-32.1 was associated with tumor recurrence in intracranial ependymomas (P < 0.001).
  • In addition to frequent gains and high-level amplification of epidermal growth factor receptor (EGFR) at 7p11.2, immunohistochemistry revealed protein overexpression to be correlated with poor prognosis (P = 0.002).
  • Moreover, EGFR might serve as therapeutic target for more specific chemotherapy applications.
  • [MeSH-major] Biomarkers, Tumor / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 1 / genetics. Ependymoma / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Receptor, Epidermal Growth Factor / genetics

  • Genetic Alliance. consumer health - Ependymoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16609018.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 9007-49-2 / DNA; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


8. Heimberger AB, Suki D, Yang D, Shi W, Aldape K: The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med; 2005 Oct 19;3:38
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The epidermal growth factor receptor (EGFR) is over expressed in approximately 50-60% of glioblastoma (GBM) tumors, and the most common EGFR mutant, EGFRvIII, is expressed in 24-67% of cases.
  • METHODS: Biopsed or partially/subtotally resected GBM patients (N = 54) underwent adjuvant conformal radiation and chemotherapy.
  • RESULTS: In our study of GBM patients with less than GTR, 42.6% (n = 23) failed to express EGFR, 25.9% (n = 14) had over expression of the wild-type EGFR only and 31.5 % (n = 17) expressed the EGFRvIII.
  • Patients within groups expressing the EGFR, EGFRvIII, or lacking EGFR expression did not differ in age, Karnofsky Performance Scale (KPS) score, extent of tumor resection.
  • They all had received postoperative radiation and chemotherapy.
  • The median overall survival times for patients with tumors having no EGFR expression, over expressed EGFR only, or EGFRvIII were 12.3 (95% CI, 8.04-16.56), 11.03 (95% CI, 10.18-11.89) and 14.07 (95% CI, 7.39-20.74) months, respectively, log rank test p > 0.05).
  • Patients with tumors that over expressed the EGFR and EGFRvIII were more likely to present with ependymal spread, 21.4% and 35.3% respectively, compared to those patients whose GBM failed to express either marker, 13.0%, although the difference was not statistically significant.
  • There was no significant difference in multifocal disease or gliomatosis cerebri among EGFR expression groups.
  • CONCLUSION: The over expressed wild-type EGFR and EGFRvIII are not independent predictors of median overall survival in the cohort of patients who did not undergo extensive tumor resection.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1122-8 [11221842.001]
  • [Cites] Invasion Metastasis. 1997;17(5):270-80 [9876221.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6962-70 [14583498.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):131-6 [15193025.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Jul;63(7):700-7 [15290895.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1462-6 [15746047.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1394-400 [1873791.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2164-72 [2009534.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6039-44 [2393868.001]
  • [Cites] J Neurosurg. 1989 Oct;71(4):487-93 [2552044.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4375-82 [7671250.001]
  • [Cites] Oncogene. 1994 Aug;9(8):2313-20 [8036013.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):809-15 [8598357.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):634-41 [8814167.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4130-40 [9307304.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):1-10 [9420066.001]
  • [Cites] Int J Oncol. 1998 Oct;13(4):717-24 [9735401.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2383-90 [9796969.001]
  • [Cites] Brain Pathol. 1998 Oct;8(4):655-67 [9804374.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Oct;24(5):381-8 [9821169.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • (PMID = 16236164.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1298339
  •  go-up   go-down


9. Takeuchi H, Kubota T, Sato K, Yao Y, Kitai R, Arishima H: Atypical neuronal-glial tumors of cerebral hemispheres in adults with PNET-like component: clinicopathological features of 5 cases. Clin Neuropathol; 2003 Mar-Apr;22(2):47-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical neuronal-glial tumors of cerebral hemispheres in adults with PNET-like component: clinicopathological features of 5 cases.
  • We investigated 5 cases with brain tumors composed ofneuronal and astrocytic differentiated tumor cells occurring in the cerebral hemispheres of adults.
  • Radiologically, contrast enhancement was demonstrated in these tumors.
  • All tumors were surgically resected following radiotherapy and chemotherapy.
  • Histologically, tumor cells were mainly composed of round or oval nucleate cells with scant cytoplasm and compactly arranged with neurocytic features.
  • Immunohistochemically, some tumor cells were immunoreactive for synaptophysin, neurofilament, beta-tubulin, chromogranin A, GFAP and vimentin.
  • Ultrastructurally, tumor cells were variably differentiated as follows: undifferentiated cells having prominent nuclei and scanty cytoplasm with inconspicuous organelles; neuronal cells consisting of neurosecretory granules or vesicles and abortive synapses, and astrocytic cells with cytoplasmic intermediate filaments.
  • These tumors were characterized as neuronal and astrocytic differentiated tumors with primitive PNET-like component.
  • However, there was little oligodendrocytic or ependymal differentiation in these tumors.
  • [MeSH-major] Neuroectodermal Tumors, Primitive / pathology. Supratentorial Neoplasms / pathology. Telencephalon / pathology
  • [MeSH-minor] Adult. Aged. Astrocytes / metabolism. Astrocytes / pathology. Cell Transformation, Neoplastic / genetics. Chromogranin A. Chromogranins / analysis. DNA / analysis. Female. Glial Fibrillary Acidic Protein / analysis. Humans. Immunohistochemistry. Loss of Heterozygosity / genetics. Male. Middle Aged. Neurons / metabolism. Neurons / pathology. Oligodendroglia / pathology. Tubulin / analysis. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12670050.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Chromogranins; 0 / Glial Fibrillary Acidic Protein; 0 / Tubulin; 0 / Vimentin; 9007-49-2 / DNA
  •  go-up   go-down


10. Maksoud YA, Hahn YS, Engelhard HH: Intracranial ependymoma. Neurosurg Focus; 2002 Sep 15;13(3):e4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this paper, the authors compiled a review of the pathological features, imaging characteristics, and treatment strategies related to this brain tumor.
  • The bibliographies of papers obtained were also checked for articles and chapters that could provide additional understanding of this tumor.
  • Malignant ependymomas and ependymomas of the spinal cord (including myxopapillary ependymomas) were excluded from this review.
  • Most authors recommend resecting as much of the tumor as is safely possible.
  • Microscopically, ependymal tumors show both epithelial and glial features.
  • Because ependymomas often recur despite surgical intervention, radiotherapy and/or radiosurgery may also play an important role in their treatment.
  • The use of chemotherapy in the treatment of these tumors, especially in the very young, is still being studied.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / surgery. Ependymoma / pathology. Ependymoma / surgery

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15844876.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


11. Aquilina K, Nanra JS, Allcutt DA, Farrell M: Choroid plexus adenoma: case report and review of the literature. Childs Nerv Syst; 2005 May;21(5):410-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: An 8-month-old infant with macrocephaly was found to have hydrocephalus and a cystic third ventricular tumour; biopsy of the tumour showed a choroid plexus adenoma.
  • The tumour was attached to the ependymal lining and was strongly adherent to the walls and floor of the anterior third ventricle.
  • TREATMENT: After biopsy, it was felt that a radical resection would carry a high risk of injury to the floor of the third ventricle and cause new neurological deficits.
  • In view of the benign nature of the tumour, no adjuvant radiotherapy or chemotherapy was given.
  • OUTCOME: There was no further tumour growth or clinical deterioration over a 6-year follow-up period.
  • [MeSH-major] Adenoma. Choroid Plexus Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Neuropathol. 1995 May-Jun;14(3):159-61 [7671458.001]
  • [Cites] Surg Neurol. 1982 Apr;17 (4):290-2 [7079955.001]
  • [Cites] Clin Neuropathol. 1991 May-Jun;10(3):137-40 [1860272.001]
  • [Cites] Neuropediatrics. 1990 Feb;21(1):55-6 [2179761.001]
  • [Cites] J Neurosurg. 1970 Nov;33(5):587-90 [5312297.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2712-9 [2187587.001]
  • [Cites] Pathol Res Pract. 1996 Aug;192(8):840-4 [8897520.001]
  • [Cites] Neurosurgery. 1998 Jul;43(1):171-3; discussion 173-4 [9657207.001]
  • [Cites] Hum Pathol. 1989 Jul;20(7):696-700 [2661411.001]
  • [Cites] Neurosurgery. 1991 Jul;29(1):130-2 [1908063.001]
  • (PMID = 15565450.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Prealbumin; 0 / S100 Proteins; 0 / Vimentin
  • [Number-of-references] 12
  •  go-up   go-down


12. Behling E, Birbe R, Veznadaroglu E, Andrews DW, Flanders A, Kenyon LC: Gliosarcoma arising from an anaplastic ependymoma: a case report of a rare entity. Hum Pathol; 2004 Apr;35(4):512-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the first case of a gliosarcoma arising from an anaplastic ependymoma and the second case of gliosarcoma arising from any type of ependymal neoplasm.
  • The patient was a 48-year-old woman with a solid and cystic, peripherally enhancing, 7-cm right frontal mass lesion.
  • The tumor recurred despite multiple cycles of postoperative radiation and chemotherapy.
  • After the fourth recurrence, the tumor displayed a biphasic pattern of differentiation.
  • The first pattern was similar to the original anaplastic ependymoma, whereas there was a second new sarcomatous pattern resembling fibrosarcoma that was admixed with and overrunning the ependymal component.
  • The spectrum of gliosarcoma is therefore expanded to include not only astrocytic and oligodendroglial components but ependymal components as well.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology. Gliosarcoma / pathology. Neoplasms, Multiple Primary / pathology. Neoplasms, Radiation-Induced / pathology
  • [MeSH-minor] Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology


13. Reni M: Guidelines for the treatment of adult intra-cranial grade II-III ependymal tumours. Forum (Genova); 2003;13(1):90-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines for the treatment of adult intra-cranial grade II-III ependymal tumours.
  • Intra-cranial ependymal tumours are very rare in the adult population, so most of reported series are retrospective, include also paediatric patients and have limited statistical power due to the small number of cases.
  • As a consequence, universally accepted prognostic factors and therapeutic guidelines are lacking.
  • The addition of postoperative chemotherapy with lomustine, vincristine and prednisone to cranio-spinal irradiation did not improve survival with respect to RT alone in a randomised phase III trial of children with infratentorial ependymoma.
  • Different chemotherapy regimens have been tested in children with ependymoma or anaplastic ependymoma yielding comparable results to those reported for patients receiving RT alone.
  • Thus far, there is no proof that the addition of chemotherapy to RT improves the outcome and adjuvant chemotherapy should be confined to investigational controlled clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14732890.001).
  • [ISSN] 1970-0008
  • [Journal-full-title] Forum (Genoa, Italy)
  • [ISO-abbreviation] Forum (Genova)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


14. Lou E: Oncolytic viral therapy and immunotherapy of malignant brain tumors: two potential new approaches of translational research. Ann Med; 2004;36(1):2-8
MedlinePlus Health Information. consumer health - Genes and Gene Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncolytic viral therapy and immunotherapy of malignant brain tumors: two potential new approaches of translational research.
  • Brain tumors arise at a rate of nearly 5/100,000 in the general population, with over 17,000 U.S. residents being diagnosed each year.
  • Approximately 60% of all brain tumors are gliomas, which are derived from interstitial tissue of the brain, such as astrocytic or ependymal tissue, or oligodendrocytes.
  • The traditional protocols for treatment of malignant gliomas include diagnostic surgery, followed by regimens of radio- and chemotherapies.
  • In the case of chemotherapy, the treatment protocols have remained nearly unchanged for over 30 years despite high mortality rates, and with little to no improvement in outcome.
  • New advances in the fields of molecular biology and immunology have resulted in new possibilities for treating malignant gliomas by targeting cellular and molecular mechanisms of tumor cells, and stand in contrast to traditional forms of treatment.
  • In the field of gene therapy, the possibility of using oncolytic viruses, such as HSV-1, for glioma therapy--specifically, of high grade astrocytomas--is being explored, and trials have begun using a replication-selective mutant strain known as G207.
  • The two examples mentioned here are discussed in this review and cited as possible improvements in the treatment of high grade astrocytomas.
  • [MeSH-major] Brain Neoplasms / therapy. Genetic Therapy. Glioma / therapy. Immunotherapy
  • [MeSH-minor] Genetic Vectors / therapeutic use. Humans. Transforming Growth Factor beta / genetics. Transforming Growth Factor beta / immunology. Transforming Growth Factor beta2. Viruses / genetics. Viruses / immunology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15000342.001).
  • [ISSN] 0785-3890
  • [Journal-full-title] Annals of medicine
  • [ISO-abbreviation] Ann. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / TGFB2 protein, human; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta2
  • [Number-of-references] 35
  •  go-up   go-down


15. De Tommasi A, De Tommasi C, Occhiogrosso G, Cimmino A, Parisi M, Sanguedolce F, Ciappetta P: Primary intramedullary primitive neuroectodermal tumor (PNET)--case report and review of the literature. Eur J Neurol; 2006 Mar;13(3):240-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intramedullary primitive neuroectodermal tumor (PNET)--case report and review of the literature.
  • Spinal primitive neuroectodermal tumors (PNET) are very rare tumors, and intramedullary localization is even less common.
  • Following the WHO 2000 classification, PNETs have been considered embryonal tumors composed of undifferentiated neuroepithelial cells with a capacity of differentiation into different cellular lines, such as astrocytic, ependymal, melanotic and muscular.
  • They have been considered to arise from a neoplastic transformation of primitive neuroepithelial cells, thereby making their presence possible in any part of the central nervous system.
  • The optimal treatment for these malignant tumors is not yet clear, although, over the years, radiotherapy has been considered the best treatment for spinal PNETs.
  • The described case is that of a 38-year-old man with a primary intra-extramedullary PNET, treated by laminectomy, open biopsy and chemotherapy.
  • The patient, 18 months after the onset of his symptomatology, died without cerebral tumor involvement.
  • [MeSH-major] Brain Neoplasms. Laminectomy / methods. Neuroectodermal Tumors, Primitive

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618339.001).
  • [ISSN] 1351-5101
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 25
  •  go-up   go-down


16. Miyake Y, Okoshi Y, Machino T, Chiba S: Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum. Int J Hematol; 2010 Oct;92(3):474-80
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum.
  • Intraventricularly administered RTX was localized specifically at the lymphoma lesions, indicating that RTX penetrated the ependymal layer of the lateral ventricle to reach the tumor lesion, where it specifically bound to the lymphoma cells.
  • Intraventricular administration of RTX and serum in a rat/human CNS lymphoma model might be a potential novel treatment for CNS lymphomas of B cell origin.
  • [MeSH-major] Antibodies, Monoclonal, Murine-Derived / administration & dosage. Antibodies, Monoclonal, Murine-Derived / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Central Nervous System Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Serum / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. Rats. Rats, Nude. Rituximab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Immunol Immunother. 2002 Mar;51(1):15-24 [11845256.001]
  • [Cites] Expert Rev Neurother. 2009 Oct;9(10):1497-509 [19831839.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3900-8 [10845926.001]
  • [Cites] Leukemia. 1998 Dec;12(12):2029-33 [9844934.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] Glia. 1998 Jan;22(1):72-85 [9436789.001]
  • [Cites] J Neurooncol. 1999 Jun;43(2):153-60 [10533727.001]
  • [Cites] Cell Immunol. 2000 Aug 25;204(1):55-63 [11006018.001]
  • [Cites] EMBO J. 1988 Mar;7(3):711-7 [2456210.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1038-43 [11807010.001]
  • [Cites] Blood. 2003 Feb 1;101(3):949-54 [12393572.001]
  • [Cites] Haematologica. 2004 Jun;89(6):753-4 [15194546.001]
  • [Cites] Pharm Res. 2005 Jul;22(7):1011-37 [16028003.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4738-45 [18552383.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2717-26 [11160337.001]
  • [Cites] Cancer Sci. 2006 Jan;97(1):80-3 [16367925.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):131-8 [16284923.001]
  • [Cites] J Exp Med. 1988 Jun 1;167(6):1975-80 [3260267.001]
  • [Cites] Cancer Sci. 2007 Sep;98(9):1368-72 [17640305.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1350-6 [17312328.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1793-800 [15172969.001]
  • [Cites] Adv Drug Deliv Rev. 1999 Apr 5;36(2-3):211-227 [10837717.001]
  • [Cites] Int J Hematol. 2009 Jun;89(5):577-83 [19353238.001]
  • [Cites] J Immunol. 2003 Aug 1;171(3):1581-7 [12874252.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1314-9 [11830481.001]
  • [Cites] Leuk Lymphoma. 2001 Aug;42(4):731-8 [11697503.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):4027-35 [16818702.001]
  • [Cites] J Cereb Blood Flow Metab. 1997 Jul;17(7):713-31 [9270488.001]
  • [Cites] Mol Genet Metab. 2005 Sep-Oct;86(1-2):141-9 [16006167.001]
  • [Cites] Blood. 2003 Jan 15;101(2):466-8 [12393404.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):1989-97 [19276270.001]
  • [Cites] Glia. 1998 Apr;22(4):348-59 [9517567.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6567-71 [14695162.001]
  • [Cites] Jpn J Clin Oncol. 2008 May;38(5):373-80 [18413337.001]
  • (PMID = 20820968.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


17. Schrot RJ, Ma JH, Greco CM, Arias AD, Angelastro JM: Organotypic distribution of stem cell markers in formalin-fixed brain harboring glioblastoma multiforme. J Neurooncol; 2007 Nov;85(2):149-57
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The role of stem cells in the origin, growth patterns, and infiltration of glioblastoma multiforme is a subject of intense investigation.
  • A 41-year-old male with a right posterior temporal glioblastoma had undergone surgery, radiation, and chemotherapy.
  • After formalin fixation, sectioning, and mapping of tumor location in the gross specimen, histologic specimens were prepared from tumor-bearing and grossly normal hemispheres.
  • Both markers co-localized to the ependymal and subependymal zones on the side of the tumor, but not in the normal hemisphere or more rostrally in the affected hemisphere.
  • The robust staining for ATF5 and CD133 in histologically normal ventricular zone suggests that an increase in periventricular stem cell activity occurred in this patient on the side of the tumor, either as a localized response to brain injury or as an integral component of oncogenesis and tumor recurrence.
  • [MeSH-major] Activating Transcription Factors / metabolism. Antigens, CD / metabolism. Brain / metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Glycoproteins / metabolism. Peptides / metabolism
  • [MeSH-minor] AC133 Antigen. Adult. Biomarkers / metabolism. Cerebral Ventricles / metabolism. Fatal Outcome. Humans. Immunohistochemistry. Male. Tissue Distribution

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurooncol. 2008 Sep;89(2):247-8; author reply 249 [18568293.001]
  • [Cites] J Neurosci. 2006 Jun 21;26(25):6781-90 [16793885.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] Acta Neuropathol. 1979 Mar 15;45(3):177-85 [442983.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):425-36 [16723989.001]
  • [Cites] J Comp Neurol. 2006 Jan 20;494(3):415-34 [16320258.001]
  • [Cites] Mol Cell Neurosci. 2005 Jul;29(3):372-80 [15950153.001]
  • [Cites] J Neurosci. 2003 Jun 1;23(11):4590-600 [12805299.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Nature. 1966 Jun 25;210(5043):1378-9 [6007120.001]
  • [Cites] Oncogene. 2006 Feb 9;25(6):907-16 [16170340.001]
  • [Cites] J Neurosci. 2005 Apr 13;25(15):3889-99 [15829641.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] J Neurosci. 2005 Jan 5;25(1):10-8 [15634762.001]
  • [Cites] Nature. 2004 Feb 19;427(6976):740-4 [14973487.001]
  • [Cites] Experientia. 1976 Nov 15;32(11):1467-8 [992001.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1313-7 [9809557.001]
  • [Cites] Cell. 1999 Jan 8;96(1):25-34 [9989494.001]
  • (PMID = 17516028.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 Antigen; 0 / ATF5 protein, human; 0 / Activating Transcription Factors; 0 / Antigens, CD; 0 / Biomarkers; 0 / Glycoproteins; 0 / PROM1 protein, human; 0 / Peptides
  •  go-up   go-down


18. Johnston DL, Keene D, Bartels U, Carret AS, Crooks B, Eisenstat D, Fryer C, Lafay-Cousin L, Larouche V, Moghrabi A, Wilson B, Zelcer S, Silva M, Brossard J, Bouffet E: Patterns of enrollment of infants with central nervous system tumours on cooperative group studies: a report from the Canadian Pediatric Brain Tumour Consortium. J Neurooncol; 2010 Sep;99(2):243-9
MedlinePlus Health Information. consumer health - Children's Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of enrollment of infants with central nervous system tumours on cooperative group studies: a report from the Canadian Pediatric Brain Tumour Consortium.
  • In children under the age of 3, the most common solid tumours are brain tumors.
  • Treatment for many of these patients includes surgery, chemotherapy and rarely radiation therapy.
  • Many clinical trials have been performed in an attempt to establish the best treatment for these patients.
  • Patients enrolled on clinical trials contribute to the establishment of the best therapy.
  • We performed a national survey of all children less than the age of three with brain tumours and examined the contribution these patients made to clinical trials.
  • A data bank was established using data collected from Canadian pediatric oncology centers on children less than age 3 diagnosed with brain tumours between 1990 and 2005.
  • Data were collected on the use of adjunctive treatment after surgery, treatment on a protocol, reasons patients were not registered on a protocol, and reasons for discontinuation of therapy.
  • From the 579 cases in the data bank, 302 (52%) patients were treated with further therapy after surgery.
  • The use of further therapy after surgery was significantly higher in patients with cerebellar and brain stem tumors, patients who were over 1 year of age, patients with ependymal and embryonal tumors, and patients with high grade malignant tumors.
  • Only 62 (21%) patients were enrolled on a protocol for therapy.
  • The therapy was stopped because of completion of the protocol in 50% and because of disease progression in 34%.
  • In Canada, about half of children under the age of 36 months with brain tumors are undergoing therapy following surgery for their malignancy but only a small fraction of them are enrolled on a clinical trial.
  • There needs to be improved availability of clinical trials for these patients so that novel therapies can be evaluated and survival improved.
  • [MeSH-major] Brain Neoplasms / epidemiology. Child Health Services / utilization. Glioma / epidemiology. Patient Participation. Patient Selection
  • [MeSH-minor] Canada / epidemiology. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Infant, Newborn. Male. Neoplasm Staging. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2007 Dec;29(12):811-4 [18090927.001]
  • [Cites] J Clin Epidemiol. 2001 Mar;54(3):217-24 [11223318.001]
  • [Cites] Lancet. 2004 Jan 24;363(9405):263-70 [14751698.001]
  • [Cites] Cochrane Database Syst Rev. 2008 Jul 16;(3):MR000009 [18677782.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):152-61 [11554387.001]
  • [Cites] Cancer. 1993 May 15;71(10 Suppl):3325-30 [8490876.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7 Suppl):1074-82 [17943961.001]
  • [Cites] Semin Oncol. 2008 Oct;35(5):484-93 [18929147.001]
  • [Cites] Cancer. 2006 Oct 1;107(7 Suppl):1645-55 [16906507.001]
  • (PMID = 20135195.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Miscusi M, Polli FM, Missori P, Delfini R: Ghost lesions in patient with cerebral-isolated neurosarcoidosis. A case report. J Neurosurg Sci; 2006 Mar;50(1):17-20; discussion 20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a case of isolated cerebral neurosarcoidosis with remitting nodular lesions resembling intraventricular neoplasms.
  • The patient, admitted at our Department for surgical treatment of a magnetic resonance imaging (MRI) demonstrated fourth ventricle lesion, presented acute intracranial hypertension.
  • A second MRI performed before the scheduled operation showed the disappearance of the fourth ventricle lesion and a tetra-ventricular hydrocephalus.
  • The patient has been treated with a third-ventriculostomy, followed, after 15 days, by ventriculoperitoneal shunt.
  • Cerebrospinal fluid analysis has been conducted and a high concentration of ACE, specific marker of neurosarcoidosis, has been found.
  • A systemic chemotherapy with azathioprine has been started, but the patient died six months later for worsening of the clinical conditions.
  • Medical treatment is based on corticosteroids and chemotherapic agents.
  • Neurosurgical intervention can be related to treat hydrocephalus due to ependymal and arachnoidal involvement or to remove large lesions.
  • In our opinion biopsy should be limited only to ACE negative patients and to those who do not respond to chemotherapy.
  • [MeSH-major] Brain Diseases / diagnosis. Brain Diseases / pathology. Cerebral Ventricle Neoplasms / pathology. Sarcoidosis / diagnosis. Sarcoidosis / pathology

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16557196.001).
  • [ISSN] 0390-5616
  • [Journal-full-title] Journal of neurosurgical sciences
  • [ISO-abbreviation] J Neurosurg Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 3.4.15.1 / Peptidyl-Dipeptidase A
  •  go-up   go-down


20. Takano T, Akahira J, Moriya T, Murakami T, Tanaka M, Goto M, Niikura H, Ito K, Mikami Y, Okamura K, Yaegashi N: Primary ependymoma of the ovary: a case report and literature review. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1138-41
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ependymoma is a glioma with differentiation toward ependymal cells that usually arises in the central nervous system.
  • Ovarian ependymoma is extremely rare, and the treatment strategies for this disease have not been established.
  • This is the first report of a patient with advanced ovarian ependymoma who received fertility-sparing surgery and is now alive without disease.
  • A 23-year-old Japanese woman, gravida 0, presented with a chief complaint of lower abdominal distension and weight loss.
  • Microscopic examination revealed a highly cellular tumor composed of small cells with hyperchromatic, round-to-oval nuclei and scanty cytoplasm.
  • Perivascular pseudorosettes, ependymal rosettes, and extensive necrosis were observed.
  • Postoperatively, she received adjuvant chemotherapy and underwent secondary cytoreductive surgery that preserved the uterus and right ovary.
  • Her menstrual cycle has resumed, and she is alive without evidence of disease 16 months after the start of treatment.
  • Although rare, primary ovarian ependymoma must be kept in mind in the differential diagnosis of ovarian tumors, especially in young women.
  • Administration of etoposide-based chemotherapy along with cytoreductive surgery is a potential standard treatment for advanced ovarian ependymoma.
  • [MeSH-major] Ependymoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Female. Gynecologic Surgical Procedures. Humans. Reoperation

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343197.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 16
  •  go-up   go-down


21. Rahman R, Osteso-Ibanez T, Hirst RA, Levesley J, Kilday JP, Quinn S, Peet A, O'Callaghan C, Coyle B, Grundy RG: Histone deacetylase inhibition attenuates cell growth with associated telomerase inhibition in high-grade childhood brain tumor cells. Mol Cancer Ther; 2010 Sep;9(9):2568-81
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histone deacetylase inhibition attenuates cell growth with associated telomerase inhibition in high-grade childhood brain tumor cells.
  • Aberrant epigenetic regulation of gene expression contributes to tumor initiation and progression.
  • Studies from a plethora of hematologic and solid tumors support the use of histone deacetylase inhibitors (HDACi) as potent anticancer agents.
  • The present study investigates the anticancer effects of the HDACi trichostatin A in high-grade childhood brain tumor cells.
  • In contrast, no cytotoxicity was observed in primary ependymal cells with respect to cilia function.
  • Thus, inhibition of histone deacetylases leads to antiproliferative and proapoptotic effects in childhood brain tumor cells, likely to involve altered chromatin regulation at the human telomerase reverse transcriptase promoter.
  • [MeSH-major] Brain Neoplasms / drug therapy. Histone Deacetylase Inhibitors / pharmacology. Histone Deacetylases / metabolism. Telomerase / antagonists & inhibitors
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Cycle / drug effects. Cell Cycle / genetics. Cell Growth Processes / drug effects. Child. Epigenesis, Genetic. Gene Expression / drug effects. Humans. Hydroxamic Acids / pharmacology. Rats. Rats, Wistar. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Brain Tumor, Childhood.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20643785.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 3X2S926L3Z / trichostatin A; EC 2.7.7.49 / Telomerase; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


22. Garcia-Barriola V, De Gómez MN, Suárez JA, Lara C, González JE, García-Tamayo J: Ovarian ependymoma. A case report. Pathol Res Pract; 2000;196(8):595-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Presence of typical ependymal rosettes and positivity to GFAP confirmed the diagnosis of ependymoma.
  • Ovarian ependymomas are rare tumors; only eight cases, to our knowledge, have been reported in the literature.
  • They have a favorable prognosis; patients with advanced stage disease are reported alive and well after treatment with surgery and chemotherapy.
  • [MeSH-major] Ependymoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Diagnostic Errors. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10982025.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


23. Hwang HJ, Sohn JH, Han SJ, Kim TS, Lee YS, Kim JH: Multi-disciplinary treatment of a rare pelvic cavity ependymoma. Yonsei Med J; 2007 Aug 31;48(4):719-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-disciplinary treatment of a rare pelvic cavity ependymoma.
  • A 27-year-old Korean female was admitted to the hospital with a sensation of abdominal fullness.
  • Histologically, the tumor was characterized by compact columnar neoplastic cells divided by fibrovascular septae.
  • The neoplastic cells formed true ependymal rosettes and perivascular pseudorosettes.
  • Immunohistochemical staining showed a strong positive reaction for glial fibrillary acidic protein (GFAP) and vimentin and a partial positive reaction for S100 and EMA.
  • The tumor was thus diagnosed as an ependymoma arising from the pelvic cavity.
  • The patient was treated with a debulking operation and chemotherapy based upon the in vitro chemosensitivity test results.
  • This is a rare case of extraneural ependymoma for which an in vitro chemosensitivity test was critical in determining the multidisciplinary approach for treatment.
  • [MeSH-major] Ependymoma / pathology. Pelvic Neoplasms / pathology

  • Genetic Alliance. consumer health - Ependymoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 2001 Feb;33(1):26-9 [11280604.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):421-3 [12946033.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3618-30 [15289487.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):203-9 [6703196.001]
  • [Cites] Mayo Clin Proc. 1992 Apr;67(4):373-8 [1548954.001]
  • [Cites] Arch Pathol Lab Med. 1985 Mar;109(3):291-3 [3838461.001]
  • [Cites] Diagn Cytopathol. 1986 Jan-Mar;2(1):62-8 [3522133.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2565-71 [2684388.001]
  • [Cites] Cancer. 1991 Jan 1;67(1):20-7 [1985717.001]
  • [Cites] Hum Pathol. 1984 Jul;15(7):632-8 [6204919.001]
  • (PMID = 17722249.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2628065
  •  go-up   go-down


24. Craver RD, Lipscomb JT, Suskind D, Velez MC: Malignant teratoma of the thyroid with primitive neuroepithelial and mesenchymal sarcomatous components. Ann Diagn Pathol; 2001 Oct;5(5):285-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant teratoma of the thyroid with primitive neuroepithelial and mesenchymal sarcomatous components.
  • A 15-year-old black girl had a near total resection of a malignant thyroid teratoma with bilateral nodal involvement and mediastinal extension.
  • A predominant neuroepithelial pattern had ependymal rosettes and mitoses, stained for neuron-specific enolase, neuron-specific B tubulin, and synaptophysin.
  • A malignant spindle cell component stained for smooth-muscle actin, muscle actin, and to a lesser extent S-100.
  • Loose myxoid tissue resembled primitive cartilage.
  • The tumor from the left and right thyroid lobes exhibited trisomy 8, the right also had hyperdiploid cell lines.
  • She was treated with aggressive combination chemotherapy and radiation.
  • Presently there is no residual disease 16 months after diagnosis.
  • Malignant thyroid teratoma is an aggressive tumor, with 15 of 27 reported patients dying 2 weeks to 3 years after diagnosis.
  • Survivors have been treated with total or subtotal resection, combination chemotherapy with agents effective in the treatment of germ cell tumors as well as sarcomas, and radiation for either recurrent or residual disease.
  • The heterologous elements, lacking MIC2 staining and t(11;22), support the diagnosis of malignant teratoma rather than a neuroepithelial tumor.
  • Trisomy 8 is the first cytogenetic abnormality described in malignant thyroid teratoma.
  • Therapy should be tailored to the management of all transformed histologies.
  • [MeSH-major] Neuroectodermal Tumors, Primitive / diagnosis. Sarcoma / diagnosis. Teratoma / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Aneuploidy. Antineoplastic Combined Chemotherapy Protocols. Biomarkers, Tumor / analysis. Biopsy, Needle. Chemotherapy, Adjuvant. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Humans. Image Cytometry. Prognosis. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company
  • (PMID = 11598856.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Number-of-references] 34
  •  go-up   go-down


25. Nakasu S, Fukami T, Baba K, Matsuda M: Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas. J Neurooncol; 2004 Dec;70(3):333-40
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas.
  • Although the expression O6-methylguanine-DNA methyltransferase (MGMT) is an important hallmark for decision of nitrosourea chemotherapy for glioma patients, no immunohistochemical method for analysis of MGMT has been standardized yet.
  • Gliomas usually contain non-neoplastic cells even deep in the tumor.
  • To clarify this point, we investigated MGMT expression in the non-neoplastic cells in autopsy and surgical specimens by immunohistochemistry.
  • High grade gliomas were also studied to find a cut-off point for treatment decision.
  • MGMT immunohistochemistry in the normal brain or brain with non-neoplastic disease revealed nuclear staining in some endothelial cells, inflammatory cells, ependymal cells, astrocytes and oligodendroglias.
  • High grade gliomas always contained an MGMT-positive non-neoplastic component.
  • Although, the endothelial cells were easily distinguished from the neoplastic cells, other cells were often mistaken for tumor cells.
  • The population of MGMT-positive non-neoplastic cells was usually less than 10%.
  • In 51 high grade glioma patients, who received both radiotherapy and chemotherapy with nimustine (ACNU), the median overall survival of the MGMT-negative group (23 months) was significantly longer than that of the MGMT-positive group (14 months) (P < 0.009).
  • In the MGMT-positive group, addition of platinum-based chemotherapy did not improve the survival.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain / metabolism. Brain Neoplasms / metabolism. Glioma / metabolism. O(6)-Methylguanine-DNA Methyltransferase / metabolism
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Male. Middle Aged. Nimustine / therapeutic use. Prognosis. Radiotherapy. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Dec;16(12 ):3851-7 [9850030.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3310-5 [9779706.001]
  • [Cites] Mutat Res. 2000 Apr;462(2-3):83-100 [10767620.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):783-8 [8631014.001]
  • [Cites] Brain Tumor Pathol. 2001;18(2):131-7 [11908869.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1715-9 [11577014.001]
  • [Cites] Neurol Res. 2003 Apr;25(3):241-8 [12739231.001]
  • [Cites] Brain Pathol. 2003 Apr;13(2):176-84 [12744471.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Lab Invest. 1998 May;78(5):643-4 [9605190.001]
  • [Cites] Int J Oncol. 2003 Mar;22(3):543-9 [12579307.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2388-99 [11981013.001]
  • [Cites] Carcinogenesis. 1996 Apr;17(4):637-41 [8625471.001]
  • [Cites] J Biol Chem. 1994 Jun 24;269(25):17228-37 [8006031.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):807-14 [10213216.001]
  • [Cites] Jpn J Clin Oncol. 1992 Jun;22(3):143-9 [1518162.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):67-72 [12455055.001]
  • [Cites] Surg Neurol. 1995 Nov;44(5):462-8; discussion 468-70 [8629231.001]
  • [Cites] Mol Carcinog. 2003 Jan;36(1):23-31 [12503076.001]
  • [Cites] Carcinogenesis. 2003 Jun;24(6):1039-44 [12807758.001]
  • [Cites] Int J Cancer. 1996 Oct 21;69(5):420-5 [8900378.001]
  • (PMID = 15662974.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0S726V972K / Nimustine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


26. Phan TG, O'Neill BP, Kurtin PJ: Posttransplant primary CNS lymphoma. Neuro Oncol; 2000 10;2(4):229-38
MedlinePlus Health Information. consumer health - Organ Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ependymal contact occurred in 5 patients.
  • Diagnostic tissue was obtained by stereotactic biopsy from 6 patients and by open biopsy from 2.
  • Slides available for review (7 patients) showed that the tumors were of CD20-positive lineage and were positive for Epstein-Barr virus, using in situ hybridization.
  • In our series, (1) PT-PCNSL presented nonspecifically and progressed rapidly, (2) stereotactic brain biopsy had significant morbidity, and (3) despite multimodal therapy, survival was poor.
  • [MeSH-major] Brain Neoplasms / etiology. Brain Neoplasms / pathology. Immunosuppressive Agents / adverse effects. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / pathology. Organ Transplantation / adverse effects
  • [MeSH-minor] Adult. Brain / drug effects. Brain / pathology. Brain / physiopathology. Cerebrospinal Fluid / chemistry. Cerebrospinal Fluid / cytology. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11265232.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30CA15083
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Other-IDs] NLM/ PMC1920594
  •  go-up   go-down






Advertisement